Nkarta, Inc. <NKTX.O>: H.C. Wainwright cuts target price to $14 from $16
NKTX•Related News
Cardinal Infrastructure Q2 revenue jumps 114% on organic and acquisition growth, raises 2026 sales guidance
CDNL•
Gain Therapeutics Q2 FY26 net loss narrows to $0.11 a share; R&D expenses fall 24.64% to $2.1 million
GANX•
Broadwind Q2 Revenue USD 24.3 Million
BWEN•
Harvard Bioscience Q2 FY26 net loss widens to $2.9 million; revenue rises 11% to $22.7 million
HBIO•
NeurAxis Q2 net loss widens 23.4% to $2.09 million year over year; net sales more than double to $1.93 million year over year
NRXS•